{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-O596QE59/d8ae40f1-4052-465b-a0fa-64a110f7ad70/PDF","dcterms:extent":"543 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-O596QE59/e452bc18-7981-4fdd-a055-463102de4978/TEXT","dcterms:extent":"30 KB"}],"edm:TimeSpan":{"@rdf:about":"1992-2025","edm:begin":{"@xml:lang":"en","#text":"1992"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-O596QE59","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S"},{"@xml:lang":"sl","#text":"Radiology and oncology (Ljubljana)"}],"dcterms:issued":"1999","dc:creator":["Borštnar, Simona","Čufer, Tanja","Rudolf, Zvonimir","Vrhovec, Ivan"],"dc:format":[{"@xml:lang":"sl","#text":"številka:1"},{"@xml:lang":"sl","#text":"letnik:33"},{"@xml:lang":"sl","#text":"str. 43-53"}],"dc:identifier":["ISSN:1318-2099","COBISSID:9752281","URN:URN:NBN:SI:doc-O596QE59"],"dc:language":"en","dc:publisher":[{"@xml:lang":"sl","#text":"Croatian Medical Association - Croatian Society of Radiology"},{"@xml:lang":"sl","#text":"Slovenian Medical Society - Section of Radiology"}],"dc:subject":[{"@xml:lang":"sl","#text":"Breast neoplasms"},{"@xml:lang":"sl","#text":"dojke"},{"@xml:lang":"sl","#text":"Plasminogen activator inhibitor 1"},{"@xml:lang":"sl","#text":"Plasminogen activator inhibitor 2"},{"@xml:lang":"sl","#text":"Prognosis"},{"@xml:lang":"sl","#text":"prognoza"},{"@xml:lang":"sl","#text":"rak (medicina)"},{"@xml:lang":"sl","#text":"Recurrence"},{"@xml:lang":"sl","#text":"Urokinase"},{"@xml:lang":"sl","#text":"urokinaze"},{"@xml:lang":"sl","#text":"zdravljenje"}],"dcterms:temporal":{"@rdf:resource":"1992-2025"},"dc:title":{"@xml:lang":"sl","#text":"Prognostic relevance of urokinase plasminogen activator and its inhibitors in patients with breast cancer| Napovedni pomen urokinaznega aktivatorja plazminogena in njegovih inhibitorjev pri bolnicah z rakom dojk|"},"dc:description":[{"@xml:lang":"sl","#text":"Urokinase plasminogen activator (uPA) and its inhibitors, PAI-1 and PAI-2, play an important role in iritercellular tissue degradation, thus promoting tumor cell invasion into the adjoining structures and metastasizing. Our studywas aimed to assess a possible prognostic value of uPA, PAI-1 and PAI-2 in a retrospective series of 87 patients with breast cancer stage I-III, whosecytosols were stored in the archives of the, Institute of Oncology in Ljubljana. The median follow-up was 35 months. The prognostic value of the established prognostic factors and uPA, PAI-1 and PAI-2 were evaluated by means of univariate statistical analysis and partial multivariate models. The obtained uPA values were very low and did not correlate with the disease free survival, whereas PAI-1 and PAI-2 significantly influenced the time to the first recurrence. Patients with PAI-1 values above 5 ng/mg proteins had statistically significantly worse disease free survival than the patients withlower PAI-1 values (58% vs. 85%). In the case of PAI-2, the situation wasjust the opposite: the patients with PAI-2 values exceeding 6.4 ng/mg proteins had statistically significantly better 3-year disease free survival than the patients with lower values (90% vs. 60%). Both, PAI-1 and PAl-2 retained their independent prognostic value, irrespective of the addition of the established prognostic factors to partial multivariate models, and only with locally advanced disease the prognostic value of PAI-1 was greater than that of PAI-2"},{"@xml:lang":"sl","#text":"Urokinazni aktivator plazminogena (u-PA), in njegova inhibitorja (PAI- 1 in PAI-2) igrajo pomembno vlogo pri razgradnji medceličnega tkiva in s tem pri prodoru tumorskih celic v okolico ter metastaziranju. Namen naše raziskave je bil ugotoviti morebitno napovedno vrednost uPA, PAI-1 in PAI-2 v retrospektivni seriji 87 bolnic z rakom dojke stadijev I-III, njihove citosolehranimo na Onkološkem inštitutu v Ljubljani. Srednja opazovalna doba je bila 35 mesecev. Napovedni pomen uveljavljenih napovednih dejavnikov ter uPA, PAI-1 in PAI-2 smo ocenjevali z univariatno statistično analizo in delnimi multivariatnimi modeli. Vrednost uPA so bile zelo nizke in niso korelirale s preživetjem brez znamenj bolezni, PAI-1 in PAI-2 pa sta značilno vplivala na čas prve ponovitve bolezni. Bolnice, ki so imele vrednost PAI-1 večjo od 5ng/mg pro- teinov, so imele statistično značilno slabše preživetje brez znamenj bolezni kot bolnice z manjšimi vrednostmi (58% vs 85% , p = 0.0046). PAI-2 je pokazal nasprotno sliko, bolnice z vred- nostmi PAI-2 večjimi od 6.4 ng/mg proteinov so imele statistično značilno boljše triletno preživetje brez znamenj bolezni kot bolnice z manjšimi vrednostmi ( 90% vs 48%, Ir= 0.0178). PAI-1 in PAI-2 sta ohranila svojo neodvisno napovedno vrednost ob dodajanju uveljavljenih napovednih dejavnikov v delne multivariatne modele in le lokalna razširjenost bolezni je pokazala večjo napovedno moč od PAI-1 in PAI-2"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-O596QE59","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-O596QE59"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-O596QE59/d8ae40f1-4052-465b-a0fa-64a110f7ad70/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Onkološki inštitut Ljubljana"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-O596QE59/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-O596QE59"}}}}